[{"id":"af305bb7-595f-4af9-bc17-4d80012623d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01103635","created_at":"2021-02-26T05:52:10.499Z","updated_at":"2024-07-02T16:36:46.439Z","phase":"Phase 1","brief_title":"Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT01103635","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imjudo (tremelimumab-actl) • CP-870893"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 05/02/2016","study_completion_date":" 05/02/2016","last_update_posted":"2020-04-07"},{"id":"695a8f0a-8022-4d0c-9439-2ec7fd2bbea6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00607048","created_at":"2021-01-18T02:15:12.023Z","updated_at":"2024-07-02T16:37:24.096Z","phase":"Phase 1","brief_title":"Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors","source_id_and_acronym":"NCT00607048","lead_sponsor":"Hoffmann-La Roche","biomarkers":" IL6 • TNFA • ICAM1 • CD40 • CD86 • FCER2","pipe":"","alterations":" ","tags":["IL6 • TNFA • ICAM1 • CD40 • CD86 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • CP-870893"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 07/01/2009","primary_completion_date":" 07/01/2009","study_txt":" Completion: 07/01/2009","study_completion_date":" 07/01/2009","last_update_posted":"2017-03-27"}]